Epithelioid Sarcoma: Treatment and Follow-Up
Wide surgical excision with negative margins (R0) is the cornerstone of treatment for epithelioid sarcoma, and regional lymph node assessment is mandatory given the uniquely high propensity for nodal metastases in this histologic subtype 1.
Surgery
Perform wide excision with a rim of normal tissue achieving R0 margins (no tumor at margin). The surgery must be carried out by a surgeon specifically trained in sarcoma treatment 1. The minimal adequate margin depends on histological response to any preoperative therapy and anatomical barriers (muscular fasciae, periosteum, epineurium) 1.
If R1 resection (microscopic positive margins) occurs, re-operation at a reference center is mandatory if adequate margins can be achieved without major morbidity 2. For R2 resection (macroscopic residual), re-operation is absolutely required, potentially with preoperative treatments if adequate margins cannot otherwise be achieved 2.
Lymph Node Assessment
Epithelioid sarcoma is one of the few soft tissue sarcomas with frequent regional lymph node metastases—this is a critical distinguishing feature 1, 2. Regional lymph node assessment through CT/MRI should be added to standard staging procedures 1, 2.
- Regional lymph node sampling or sentinel lymph node biopsy is required for epithelioid sarcoma, even without clinically enlarged nodes 3, 4
- Pre-treatment imaging identifies lymph node enlargement in most cases with nodal involvement 3
- Nodal metastases occur in approximately 18-36% of epithelioid sarcoma cases 3, 5, 6
- Therapeutic lymph node dissection should be performed if nodes are involved 7
Radiotherapy
For high-grade, deep lesions >5 cm: postoperative radiotherapy at 50-60 Gy (1.8-2 Gy fractions) with possible boost to 66 Gy is standard treatment 1, 2. Radiotherapy can be omitted only for truly compartmental resections where the tumor was entirely contained within the compartment 2.
For high-grade, deep lesions <5 cm, radiotherapy should also be administered after surgery 2.
Preoperative radiotherapy (typically 50 Gy) is an alternative, particularly when postoperative radiotherapy would be problematic 1, 2.
For patients with regional lymph node metastases who undergo lymph node dissection, adjuvant radiotherapy should be considered for patients with a large number of tumor-positive nodes and/or extranodal spread, balancing local control benefits against lymphedema risk 1.
Chemotherapy
Adjuvant chemotherapy is NOT standard treatment but can be offered to high-risk patients (high-grade, deep, >5 cm) as an option for shared decision-making 1. The evidence is conflicting—meta-analyses show limited benefit in relapse-free and overall survival, but the largest individual trials were negative 1.
For patients with regional lymph node metastases, more aggressive multimodal treatment including chemotherapy should be considered, as this represents likely systemic disease 1, 2, 1. Chemotherapy may be administered preoperatively, at least in part 2, 1.
For unresectable or metastatic disease:
- First-line: single-agent doxorubicin 8
- Combination doxorubicin plus ifosfamide may be considered where response would facilitate other treatments 8
- Regional hyperthermia combined with systemic chemotherapy showed local control and disease-free survival advantage in one large randomized phase III trial 1
- Isolated limb perfusion with TNF-α plus melphalan is an option for extremity tumors 1, 2, 9
Targeted Therapy
Tazemetostat, an EZH2 methyltransferase inhibitor, has shown promising results specifically for epithelioid sarcoma 4. This represents an emerging targeted option given the characteristic loss of SMARCB1/INI1 in this disease.
For tumors with specific molecular alterations, NTRK inhibitors should be considered for NTRK-fusion positive tumors 8.
Follow-Up
Follow-up should include clinical evaluation and cross-sectional imaging. Given the high rates of local recurrence (30-52%) and the propensity for lymph node and pulmonary metastases, surveillance must be aggressive 10, 5, 7, 6:
- Chest CT scan for pulmonary metastases surveillance
- Regional lymph node assessment (clinical and imaging)
- Initial follow-up every 3-6 months, extending to annually after 5 years 8
- Median time to recurrence is approximately 0.9 years (range 0.1-2.3 years) 11
Critical Prognostic Factors
Tumor size >5 cm, local recurrence, presence of lymph node metastases, and incomplete resection are significant predictors of poor survival 7, 11. Patients with isolated lymph node metastases have significantly better outcomes (5-year OS ~85%) compared to those with additional extranodal metastases (5-year OS ~15%) 3.
Common Pitfalls
- Failing to assess regional lymph nodes: Unlike most soft tissue sarcomas, epithelioid sarcoma requires routine nodal evaluation
- Inadequate initial resection: The optimal time for curative resection is at primary presentation—inadequate initial surgery significantly worsens outcomes 8
- Delayed diagnosis: Epithelioid sarcoma is often misdiagnosed due to its slow-growing nature and confusing clinical presentation 12
- Underestimating metastatic potential: This tumor is aggressive with high rates of recurrence and metastases despite appearing indolent 10, 7